Glycosphingolipid Microarray
Overview
To satisfy our customers' scientific needs in exploring the structures of glycosphingolipids (GSLs), CD BioGlyco's dedicated research teams have developed GSLs microarray analysis techniques to help customers analyze multiple samples simultaneously and provide valuable glycan-binding information. Our efficient and professional services will help our clients accelerate their research progress.
Introduction
GSLs are ubiquitous glycoconjugates found on cell membranes and they have important functions in many biological processes such as signal transduction, cell adhesion, embryonic development, and carcinogenesis. Understanding the role and immunological interactions of abnormally expressed glycolipids may be critical for the development of therapeutic agents for cancer and neurological diseases. However, identifying unknown GSL-glycan structures remains a major challenge.
Over the past few years, developments in MS-based technologies have offered valuable insights into the structural analysis of GSLs through the combination of efficient separation techniques and high-resolution MS. However, the complexities of biosynthesis, structure, and function of GSL increase the difficulty of GSL structural analysis.
Key Technologies
Our GSL microarray integrates a structurally defined, curated collection of GSLs covalently immobilized onto solid surfaces, including glass substrates, forming dense, multiplexed arrays. This platform facilitates simultaneous, high-throughput screening of target molecule binding specificities across diverse GSL architectures. Engineered for exceptional specificity and sensitivity, the arrays detect subtle variations in glycan recognition events. The methodology remains compatible with orthogonal analytical techniques—notably mass spectrometry—delivering structural validation and granular analysis of GSL glycans. Rigorous immobilization chemistry ensures reproducible ligand presentation, enabling robust interrogation of glycan-protein interactions.
Mapping GSLs, Defining Disease Signatures.
We offer a comprehensive suite of services centered around the GSL microarray. We accommodate various sample types, including purified proteins, antibodies, and complex biological fluids such as serum, plasma, or cell lysates. Our services include the determination of glycan-binding specificity, glycan-binding affinity, and the identification of novel GSL-binding partners. Our platform is well-suited for a wide range of applications, from fundamental research to preclinical and clinical studies. We are committed to working closely with clients to design the most effective experimental plan to achieve their research goals.
Our streamlined workflow is designed to provide a seamless experience, guiding your project from initial sample submission to the delivery of actionable data.
- Sample Preparation and Labeling
Your sample, which can be a purified protein, antibody, or complex mixture such as serum, is prepared and labeled with a fluorescent tag. This ensures that any binding events on the array can be accurately detected by a scanner.
- Microarray Incubation
The labeled sample is incubated on the GSL microarray slide under optimized conditions. During this step, any GSL-binding proteins or molecules in your sample will bind specifically to their corresponding glycans on the array.
- Washing and Signal Detection
Non-specifically bound molecules are washed away, and the microarray is scanned with a high-sensitivity fluorescent scanner. This generates a raw data image of the binding signals.
- Data Analysis
The raw image data is processed using specialized bioinformatics software. This involves quantifying the binding intensity for each GSL spot, normalizing the data, and performing statistical analysis to identify significant binding interactions.
- Comprehensive Reporting
We deliver a detailed report that includes the raw data, processed results, and a clear visualization of the binding profile. Our expert team is available to help you interpret the findings and discuss their biological implications.
Workflow
Publication Data
DOI.: 10.1038/s41467-017-02747-y
Journal: Nature Communications
Published: 2018
IF: 14.7
Results: This study introduces a multiplex glycan bead array platform for high-throughput analysis of glycan-binding proteins. The authors covalently conjugated 184 diverse glycans to spectrally coded Luminex beads, enabling simultaneous screening of glycan-binding protein interactions across 384 samples per assay. They validated MGBA's specificity using 39 plant lectins (e.g., RCA-I binding to Gal-β4-GlcNAc motifs), 13 recombinant antibodies, and mammalian glycan-binding proteins (e.g., siglec-5, E-selectin), demonstrating reproducible glycan recognition profiles. The platform's utility was highlighted by profiling natural anti-glycan antibodies in 961 human sera, revealing IgM clusters associated with blood group antigens (e.g., anti-BGH antibodies). Crucially, MGBA identified ovarian cancer biomarkers, showing that elevated IgG against glycan #11 (Gal-α3-Gal-β4-Glc) correlated with poor survival (HR=4.12, p=0.002), while anti-blood group-A antibodies (#54) predicted better outcomes. This scalable technology bridges glycomics and clinical research by enabling population-scale glycan-binding protein studies.
Advantages
- Our microarray delivers robust, high-throughput glycan-binding data in a simple assay format, requiring only a small sample volume—ideal for efficient screening and validation without compromising accuracy.
- We guarantee unrivaled sensitivity and specificity in detecting interactions, thanks to our advanced immobilization technology, artificially synthesized GSL glycan epitopes.
- Our service supports diverse applications, from evaluating protein, antibody, or cell interactions to studying viral, bacterial, or vesicle binding.
Application
- Altered GSL expression is a key characteristic of many cancers. Our service helps researchers identify changes in GSL expression patterns and profile the binding of antibodies or lectins, leading to the discovery of new biomarkers for early detection and therapeutic targets.
- GSLs are critical for immune cell function and recognition. The array can be used to profile the binding of autoantibodies or immune receptors to different GSLs, aiding in the investigation of autoimmune diseases and the development of immunotherapies.
- GSLs are highly abundant in the nervous system and are involved in processes like neuronal development and signaling. Our service can be used to study the role of GSLs in neurological disorders and identify potential therapeutic targets.
Frequently Asked Questions
Associated Services
While our GSL microarray analysis service provides critical insights into aberrant glycan expression patterns, translating these findings into actionable therapeutic strategies often requires targeting the underlying glycosylation machinery. This is where our specialized suite of Metabolic Interconversion Inhibitor Development Services becomes invaluable. We develop targeted agents against key nucleotide sugar transporters and metabolizing enzymes, including inhibitors for:
- UDP-Glucose Inhibitor Development Service
- UDP-Galactose Inhibitor Development Service
- UDP-N-Acetylgalactosamine Inhibitor Development Service
- UDP-N-Acetylglucosamine Inhibitor Development Service
- UDP-Xylose Inhibitor Development Service
- UDP-Glucuronic Acid Inhibitor Development Service
- GDP-Fucose Inhibitor Development Service
- GDP-Mannose Inhibitor Development Service
- CMP-Sialic Acid Inhibitor Development Service
CD BioGlyco is committed to technological innovation and development in the field of glycobiology. Our GSL microarray analysis service allows for simultaneous large-scale analysis, providing glycan patterns and detailed linkage information of GSL-glycans. Please contact us directly if you need technical support, we will try our best to provide you with the best solution.
Reference
- Purohit, S.; et al. Multiplex glycan bead array for high throughput and high content analyses of glycan binding proteins. Nature Communications. 2018, 9(1): 258. (Open Access)
- Glyco™ Synthesis Platform
- Custom Glycoprotein Synthesis
- Custom Glycoside Synthesis
- Custom Glycosyl Donor Synthesis
- Custom Thioglycoside Synthesis
- Custom Phosphatidylinositol Synthesis
- Custom Cyclodextrin Synthesis
- Custom Rhamnolipid Synthesis
- Custom Sphingolipid Synthesis
- Custom Building Block Synthesis
- Carbohydrate Manufacturing
- Synthesis Process Development and Optimization
- Custom Carbohydrate Synthesis
- Custom Glycolipid Synthesis
- Custom Glycopeptide Synthesis
- Custom Glycoconjugate Synthesis
- Custom Sugar-Nucleotide Synthesis
- Nucleoside & Nucleotide Synthesis Service
- Custom Oligonucleotide Synthesis Service
- Polynucleotide Synthesis Service
- Nucleoside & Nucleotide Modification Service
- Oligonucleotide Modification Service
- Nucleoside-based Production Service
- Nucleotide-based Production Service
- OPME-based NDP-sugar Synthesis Service
- OPME-based NMP-sugar Synthesis Service
- Glycomics Platform
- Glycoproteomics Platform
- N-Glycoproteomics of PDX Models
- Nanotechnologies for the Detection of Glycopeptides
- Glycoprotein Enrichment
- Glycoprotein Quantification
- Glyco-biomarker Detection Service
- Glyco-biomarker AFP Detection Service
- Glyco-biomarker CA19-9 Detection Service
- Glyco-biomarker CA125 Detection Service
- Glyco-biomarker CA15–3 Detection Service
- Glyco-biomarker CEA Detection Service
- Glyco-biomarker PSA Detection Service
- Glyco-biomarker Immunoglobulin G (IgG) Detection Service
- Glyco-biomarker Haptoglobin (Hp) Detection Service
- Glyco-biomarker α1-Antitrypsin (A1AT) Detection Service
- Glyco-biomarker α1-Acid Glycoprotein (AGP) Detection Service
- Glyco-biomarker Ceruloplasmin (CP) Detection Service
- Glyco-biomarker Fetuin A Detection Service
- Site Occupation
- Glycoprotein Structure Analysis
- Glycosylation Site-specific Antibody-Drug Conjugate (ADC) Development Platform
- Carbohydrate-based Glycomedicine Development Platform
- By Sources of Carbohydrate
- By Types of Carbohydrate
- Monosaccharides-based Glycomedicine Development
- Disaccharides-based Glycomedicine Development
- Trisaccharides-based Glycomedicine Development
- Oligosaccharides-based Glycomedicine Development
- Polysaccharides-based Glycomedicine Development
- Glycosides-based Glycomedicine Development
- Glycopeptide-based Glycomedicine Development
- Glycomimetic-based Glycomedicine Development
- By Applications of-based Glycomedicines
- Carbohydrate-based Anticoagulant Glycomedicine Development
- Carbohydrate-based Cardiovascular Glycomedicine Development
- Carbohydrate-based Antitumor Glycomedicine Development
- Carbohydrate-based Antidiabetic Glycomedicine Development
- Carbohydrate-based Antibacterial Glycomedicine Development
- Carbohydrate-based Antiviral Glycomedicines Development
- Carbohydrate-based Antiparasiti Glycomedicine Development
- By Discovery Strategies
- Glycoengineering-based Glycomedicine Development
- Production of Food Ingredients
- Multi-omics Platform for Cancer Glucose Metabolism (MOPCGM)
- Cancer Cell Glycolytic Analysis
- Cancer Cell TCA Cycle Analysis
- Cancer Cell PPP Analysis
- Gene-level Regulation Analysis of Cancer Glucose Metabolism
- Interplay Between Glucose Metabolism Reprogramming and Tumorigenesis & Progression
- Interplay Between Glucose Metabolism Reprogramming and Proliferative Signaling
- Interplay Between Glucose Metabolism Reprogramming and Growth Suppressor
- Interplay Between Glucose Metabolism Reprogramming and Cancer Cell Death
- Interplay Between Glucose Metabolism Reprogramming and Replicative Immortality
- Interplay Between Glucose Metabolism Reprogramming and Angiogenesis
- Interplay Between Glucose Metabolism Reprogramming and Invasion & Metastasis
- Interplay Between Glucose Metabolism Reprogramming and Immune Escape
- Interplay Between Glucose Metabolism Reprogramming and Genomic Instability
- Interplay Between Glucose Metabolism Reprogramming and Tumor-associated Inflammation
- Glucose Metabolism-Microenvironment Crosstalk Analysis in Cancer
- Cancer Glucose Metabolism In Vivo Analysis
- Applications of Studing Cancer Glucose Metabolism
- Discovery of Cancer Glucose Metabolism Small Molecule Inhibitor
- Discovery of Cancer Glucose Metabolism Therapeutic Monoclonal Antibodies
- Development of Gene Therapy Targeting Cancer Glucose Metabolism
- Discovery of Cancer Glucose Metabolism CAR-T Therapy Targeting
- Discovery of Cancer Glucose Metabolism Combination Therapy Strategy
- Discovery of Cancer Glucose Metabolism Precision Therapeutic Strategies
- Glycoengineering Platform
- Therapeutic Nucleic Acid Development Platform
- Therapeutic Oligonucleotide Synthesis Service
- siRNA Synthesis
- miRNA Synthesis
- ASO Synthesis
- Aptamer Synthesis
- PMO Synthesis
- sgRNA Synthesis
- Circular RNA Synthesis
- PNA Synthesis
- Lipid-based GalNac-RNA Delivery Service
- CpG Oligonucleotide Synthesis
- Click-based GalNac-RNA Delivery Service
- AntimiR Synthesis
- GalNAc-siRNA Delivery Service
- tRNA Synthesis
- GalNAc-ASO Delivery Service
- saRNA Synthesis
- Reporter Gene mRNA Synthesis
- Gene Editing mRNA Synthesis
- Gene Replacement mRNA Synthesis
- Cre Recombinase mRNA Synthesis
- hEPO mRNA Synthesis
- OVA mRNA Synthesis
- Therapeutic Oligonucleotide Modification Service
- Therapeutic Oligonucleotide Delivery Development Service
- Targeted Ligand and Linker Synthesis
- Monoantennary GalNac-RNA Delivery
- Biantennary GalNac-RNA Delivery
- Triantennary GalNac-RNA Delivery
- Tetra-antennary GalNac-RNA Delivery
- Solution Phase-based GalNac-RNA Delivery
- Solid Phase-based GalNac-RNA Delivery
- mRNA Poly(A) Tail Length Analysis
- GalNAc-siRNA Delivery
- GalNAc-ASO Delivery
- GalNAc-miRNA Delivery
- GalNAc-Aptamer Delivery
- GalNAc-AntimiR Delivery
- GalNAc-mRNA Delivery
- GalNAc-PNA Delivery
- Peptide-Therapeutic Oligonucleotide Delivery
- LNP-Therapeutic Oligonucleotide Delivery
- PEG-Therapeutic Oligonucleotide Delivery
- Biological Evaluation Service for Therapeutic Oligonucleotide
- mRNA-based Vaccine Development Service
- mRNA Sequence Design&Optimization Service
- mRNA Integrity Analysis ServicemRNA Integrity Analysis Service
- mRNA Biodistribution Analysis Service
- DNA Template Preparation Service
- mRNA Purity Analysis Service
- T Cell Cytokine Secretion Analysis Service
- mRNA Modification Service
- mRNA Length Analysis Service
- mRNA Purification Service
- Neutralizing Antibody Assay Service
- mRNA-LNP Formulation and Encapsulation Service
- mRNA Structural Characterization
- mRNA Structural Characterization Service
- mRNA Bioanalysis Service
- mRNA Residual DNA Template Analysis Service
- mRNA Residual Double-Stranded RNA (dsRNA) Analysis Service
- mRNA Size Analysis Service
- mRNA Polydispersity Analysis Service
- mRNA Zeta Potential Analysis Service
- mRNA Lipid Composition Analysis Service
- Oligonucleotide Drug Process and Formulation Development Service
- RNA Drug Process and Formulation Development
- Therapeutic Oligonucleotide Synthesis Service
- Glycobiology Microarray Platform
- Glyco™ Vaccine Development Platform
- Carbohydrate-based Vaccine Development
- Polysaccharide Vaccine Development
- Tumor-Associated Carbohydrate Vaccine Development
- Glycoconjugate Vaccine Development
- Natural Carbohydrate-based Vaccine Development
- Semi-synthetic Carbohydrate-based Vaccine Development
- Fully Synthetic Carbohydrate-based Vaccine Development
- Carbohydrate-based Antibacterial Vaccine Development
- Carbohydrate-based Antifungal Vaccine Development
- Carbohydrate-based Antiparasitic Vaccine Development
- Carbohydrate-based Antiviral Vaccine Development
- Carbohydrate-based Anticancer Vaccine Development
- Carbohydrate-based Antihelmintic Vaccine Development
- Monovalent Carbohydrate-based Vaccine Development
- Polyvalent Carbohydrate-based Vaccine Development
- Carrier Protein Design Service
- Carbohydrate Conjugation Service for Vaccine Development
- Carbohydrate-based Adjuvant Development
- Lipopolysaccharide-based Adjuvant Development
- Bacterial Outer Membrane Vesicles (OMVs)-based Adjuvant Development
- Trehalose Glycolipid-based Adjuvant Development
- Galactosylceramide-based Adjuvant Development
- Peptidoglycan-based Adjuvant Development
- Chitin/Chitosan-based Adjuvant Development
- Inulin-based Adjuvant Development
- Mannans-based Adjuvant Development
- Alginate-based Adjuvant Development
- Saponin-based Adjuvant Development
- α-Glucan-based Adjuvant Development
- Lentinan-based Adjuvant Development
- β-Glucans-based Adjuvant Development
- Deltin-based Adjuvant Development
- Muramyldipeptide-based Adjuvant Development
- Cord Factor-based Adjuvant Development
- Zwitterionic Polysaccharide-based Adjuvant Development
- Novel Plant Polysaccharides-based Adjuvant Development
- Glycoprotein-based Vaccine Development
- Glycopeptide-based Vaccine Development
- Carbohydrate-based Vaccine Development
- Glycogenomics Platform
- Glycogene Editing Service
- Glycogene Delivery Service
- Glycogene Expression Profiling
- Cancer Glycogene Discovery Service
- Glycogene Discovery Service in Cervical Cancer
- Glycogene Discovery Service in Leukemia
- Glycogene Discovery Service in Bladder Cancer
- Glycogene Discovery Service in Colorectal Adenocarcinoma
- Glycogene Discovery Service in Liver Cancer
- Glycogene Discovery Service in Lymphoma
- Glycogene Discovery Service in Breast Cancer
- Glycogene Discovery Service in Prostate Cancer
- Glycogene Discovery Service in Pancreatic Cancer
- Glycogene Discovery Service in Lung Cancer
- Glycogene Discovery Service in Thyroid Cancer
- Glycogene Discovery Service in Ovarian Cancer
- Glycan Display Platform
- Traditional Glycan Display Array
- Natural Oligosaccharide Library Construction Service
- Chemical Synthesis-based Oligosaccharide Library Construction Service
- Enzymatic Synthesis-based Oligosaccharide Library Construction Service
- Modular Synthesis-based Oligosaccharide Library Construction Service
- Oligosaccharide Library Immobilization Service
- Cell-based Glycan Display Array
- Neoglycolipid (NGL) Display Array
- Liquid Glycan Display Array (LiGA)
- Glycophage Display
- N-linked Glycoprotein-based Glycophage Display System Construction Service
- O-linked Glycoprotein-based Glycophage Display System Construction Service
- Glycophage Display-based Glycosylase Genetic Analysis Service
- Glycophag Display-based Glycoarray Service
- Glycophage Display-based Antibody Development Service
- Glycophage Display-based Epitope Mapping Service
- Glycophage Display-based Biomarker Development Service
- De Novo Glycan Display
- Cell-Surface Glycan Editing
- Examining the Effects of Altering Blood Group Antigens on Erythrocyte Cell Surfaces
- Preventing Cellular Rejection During Transplantation
- Modulating Chemical Composition and Physical Parameters of Glycocalyx
- Tailoring Cell Membranes with Biologically Active Glycans
- Targeting Glycosaminoglycan-mediated Growth Factor Signaling to Influence Stem Cell Specification
- Long-term De Novo Glycan Display for Directing Stem Cell Fate
- Traditional Glycan Display Array
- GlycoNano™ Platform
- Glyconanoparticle Development Service
- Techniques for Glyconanoparticle Development
- Carbohydrate-based Nanoparticle Production
- Gold Glyconanoparticle Production
- Silver Glyconanoparticle
- Magnetic Glyconanoparticle
- Quantum Dot (QD) Glyconanoparticle
- Glyconanoparticle Characterization
- PEG Glyconanoparticle
- Carbon-based Glyconanoparticle
- Fluorescent Glyconanoparticle
- Silica Glyconanoparticle
- Liposome Glyconanoparticle
- Glycol Nanohydrogel Development
- Glycol Nanorod
- Glycol Nanotube
- Glycol Nanocrystal/Nanosheet/Nanosphere/Nanofiber
- Glyconanoparticle Preclinical Study
- Glyconanoparticle Formulation
- Glyconanotechnology-based Biosensor Development
- GlycoNano™ Bioink Production for 3D Printing
- Glyconanoparticle Development Service
- Glyco™ Synthesis Platform





